chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I felt like I was hit by a truck in my neck, arms, and body 2 days after the second  Covid 19 shot.  My neck ,arms and torso had muscle pains.   Currently, I do not have torso pains, but my upper under arms feel like I have been lifting weights everyday, and my right side of my neck and shoulder is always sore.
Site: Pain at Injection Site-Mild, Systemic: Dizziness / Lightheadness-Mild, Systemic: tingling L hand, feeling prickly, hot-Mild, Systemic: Flushed / Sweating-Medium, Systemic: Shakiness-Medium
This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. No information regarding the patient's concurrent conditions, medical history and drug reactions or allergies was provided. On 13-JUN-2017, the patient was vaccinated with an improperly stored dose of PROQUAD injection (lot # M041508, expiration date: 09-APR-2018; exact dose and route of administration were not reported). The dose of the vaccine was reconstituted with properly stored sterile diluent (MERCK) injection. The reporter stated that the administered dose of PROQUAD was stored at the temperature of -9 to 8 degrees Celsius (C) for 18 hours 52 minutes, on unknown dates. Previous temperature excursions included storage at the temperature of -9 to 8 degrees C for 13 hours 37 minutes, on unknown dates. Data logger was used to detect temperature excursions. No adverse effects were reported. No product quality complaint was involved. Additional information has been requested.
Migraine; Headache; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of MIGRAINE (Migraine) and HEADACHE (Headache) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event. Concomitant products included Eliquis                                                        Heart and Metoprolol                                                     Heart for Heart disorder, Amlodipine                                                     Hypertension for Hypertension.    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Jan-2021, the patient experienced HEADACHE (Headache). On 17-Jan-2021, the patient experienced MIGRAINE (Migraine). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 29-Jan-2021, MIGRAINE (Migraine) and HEADACHE (Headache) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 66-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 20Oct2022 at 15:00 as dose 5 (booster), single (Lot number: GJ6665) at the age of 66 years, in right arm for covid-19 immunisation; BNT162b2 (BNT162B2), on 22Mar2021 at 15:00 as dose 1, single (Lot number: ER2613), in right arm, on 15Apr2021 at 15:00 as dose 2, single (Lot number: EW0151), in right arm, on 14Oct2021 at 15:00 as dose 3 (booster), single (Lot number: FF2590), in right arm and on 18May2022 at 15:00 as dose 4 (booster), single (Lot number: FM9992), in right arm for covid-19 immunisation. The patient had no relevant medical history. The patient took concomitant medications. Past drug history included: Septra, reaction(s): "Drug allergy"; Sulphur, reaction(s): "Drug allergy". The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Feb2023, outcome "unknown" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: negative, notes: Tested negative on tenth and eleventh days after original onset of COVID symptoms; negative, notes: Tested negative on tenth and eleventh days after original onset of COVID symptoms; Positive, notes: Tested positive again. Therapeutic measures were taken as a result of vaccination failure, covid-19.Clinical course: Paxlovid used for COVID 19 Treatment from 11Feb2023 to 16Feb2023. Paxlovid Covid rebound, asymptomatic. Seven days after finishing 5 days of Paxlovid. Tested negative on tenth and eleventh days after original onset of COVID symptoms. Two days later (today)tested again (no new symptoms or return of symptoms, just a precaution). Tested positive again.
1.5cm warm indurated SQ nodule in lt thigh t100.1 R;
Received telephone call from patient's mother 4:30 pm 9/08/08.  Reports patient received #3 HPV injection this am at 8:30 am - since receiving injection, patient with complaints of feeling "light headed, dizzy and tired".  Also complaints of pain to arm - Enc M.D. follow up: immediately.
Patient reported that 8 days after vaccination, she started feeling "hot under the skin, like menopause."  (Patient vaccinated 2/11/21, adverse effect reportedly started 2/19/21).  She did not have a fever.  These "hot flashes" would come and go, and were still occurring when she called me on 2/23/21. The patient reported feeling more short of breath than usual, although she also reported a history of COPD.  Patient also reported she takes clozapine and the dose had been reduced by her psychiatrist between 2/8/21 and 2/15/21 due to "low blood count." The patient did report these adverse effects to both her primary physician and psychiatrist.
pt recvd vax; devel pneumonia & was hosp on ventilator assistance;died 31oct95;no autopsy performed;COD pneumonia & resp arrest;
12 hours after receiving vaccination the first onset of symptoms began.  Beginning with body ache, followed by Fever, Chills, Headache, and Fatigue.  Symptoms persisted for 36 hours, with fatigue remaining.   Fatigue and minor headache have not yet fully resolved 50 hours after injection.
This case was reported by a physician via sales rep and described the occurrence of pain in arm in a adolescent female patient who received BEXSERO. On an unknown date, the patient received BEXSERO. On an unknown date, 3 days after receiving BEXSERO, the patient experienced pain in arm, injection site erythema, injected limb mobility decreased and injection site pain. On an unknown date, the outcome of the pain in arm, injection site erythema, injected limb mobility decreased and injection site pain were recovered/resolved. It was unknown if the reporter considered the pain in arm, injection site erythema, injected limb mobility decreased and injection site pain to be related to BEXSERO. This case was reported by a physician via sales rep and described the occurrence of pain in a adolescent female patient who received BEXSERO. On an unknown date, the patient received BEXSERO. On an unknown date, 3 days after receiving BEXSERO, the patient experienced pain, injection site erythema, movement disorder and injection site pain. On an unknown date, the outcome of the pain, injection site erythema, movement disorder and injection site pain were recovered/resolved. It was unknown if the reporter considered the pain, injection site erythema, movement disorder and injection site pain to be related to BEXSERO. Additional details were provided as follow: The age at vaccination was not reported. The patient received BEXSERO in an unknown arm. The patient experienced shooting pain down to her arm and elbow, injection site redness, difficulty moving arm and achiness at injection site. Limited information was provided by the sale representative from the physician. This case has been lined with case US2017026064, US2017026065 and US2017026068 as reported by same reporter.
I had a mild fever for a day after receiving the vaccine. Adverse event/ symptoms date 03/12/2023. Tested positive 03/13/2023, called doctor on the same day and was prescribed PAXLOVID for 5 days. Tested negative on 03/23/2023.  COVID-19 rebound tested positive on 03/27/2023. Finally tested negative on 04/03/2023. I had a cough for a long time. As of today, I do not have any lingering COVID-19 symptoms.
patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 32-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was provided.  It was reported that there had been no power outages that would have impacted the Moderna vaccine. However, the Healthcare professional reiterates that because her facility was unable to download the digital data logger, they would need to treat this issue as a temperature excursion. The data logger was unable to download for the months of Dec-2021, Jan-2022, and Feb-2022. They were filling out a temperature excursion assessment with the region at this time. It was reported that no adverse reactions were reported by any patients.  No treatment medication was provided.
I felt fine after the shot didn't have arm pain. I continued to feel fine that day and the next till approximately 20 hours post the shot. I started with a fever and general symptoms expected. I took a COVID-19 test and it was negative. 24 hours later my knees, ankles, elbows, back were painful and swelling. I did have muscle pain as well but this was actual joint pain. I've continued to have that. The fever had been on and off until 10/24. The fever wasn't high it was 99.9 the highest, and was upon exertion I was also fatigued. The joint problem isn't getting better but getting worse. I am waiting to try and get in to see a doctor at this point.
This spontaneous report as received from a Registered Nurse refers to 4 patient of unknown age and gender. On 15-SEP-2014 the patients were vaccinated with MMR II (therapy type, dose, route, lot # and expiration date were not reported) that had been improperly stored. No adverse effects were reported. No PQC (product quality complaint) was involved. This is one of several reports received from the same reporter. Additional information has been requested.
pt stated that her left leg around the groin area  in the muscles started to hurt.  She had severe pain in the left lower back.  She also had muscle spasms in the top part of her back then got nausea and vomited.  No fever.  Pt will call her PCP for medical advice.
This is a spontaneous report from a non-contactable consumer reporting for himself. This 66-year-old male consumer received PREVNAR 13 on an unspecified date, at single dose, in arm, for immunization. Medical history and concomitant medications were not reported. On an unspecified date the consumer experienced pain and limitation of arm movement in the arm where the injection was received. He had some pain also in his other arm, but not as much as the pain where he received Prevnar 13 injection. Events outcome was unknown. No follow-up attempts are possible, information about batch number cannot be obtained.
Night sweats; little shortness of breath; white dots on back of throat; Throat pain; bunch of bumps on the back of her tongue/throat; little cough; This is a spontaneous report from a contactable consumer (patient). A 41-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection, Lot number EL3248) via an unspecified route of administration in left arm on 12Jan2021 as unknown, single dose for covid-19 immunization. The patient's medical history and concomitant medications were not reported. It was also reported that on 12Jan2021 patient took the Pfizer COVID vaccine and 3 days later i.e., on 15Jan2021, she had night sweats and a little shortness of breath, like upstairs, or if she runs too fast, or talks too much, that was pretty much for two weeks now, then the last 2 days she had white dots, white dots in the back of her throat, and she went to urgent care and it was negative for strep, she was prone to strep. They said it was not strep, she was having throat pain, and now that morning, she had a bunch of bumps on the back of her tongue, and she was given Clindamycin, she wondered if the throat pain was related to the vaccine, she got tested for strep, and they said it was negative so now maybe it was related to the vaccine. Night sweats outcome: if she puts on a fleece blanket, which she loves to as she was always cold, but now she cannot unless she was waking up with a drenching sweat, and she did not sweat. She did not call about the sweats, since she thought she was 41, and it maybe that, but then with more thought it could be the vaccine. She did light jogs up and down stairs, she walked all over the hospital, and never got out of breath, and now she had to stop and breathe in deep. She had a little cough every now and then, and when she went to urgent care, because of the cough and her throat hurting, they did a COVID test, and it was negative. She told them she got vaccinated, they said they would still do the test, it was a rapid COVID, in the office strep and they put strep in the lab for 3 days. For white dots: her throat was hurting a while, and she looked with a flashlight and saw white dots, now states this was more than 3 days ago, the test took 3 days, so this was 4 or 5 days since she saw white dots. Last night, she did not see before the bumps in the back of her throat, she thought she had food in the back of her throat, she felt something there, and she looked at it with a flashlight and now she has bumps in the back of her throat, she tried to remove what was in the back of her throat. She did not see the white dots anymore, before the test came in, when they saw white dots. Treatment included clindamycin which was at home and she has not started. On an unspecified date in Jan2021, the patient underwent lab tests and procedures which included rapid COVID test and strep test with results of negative. The outcome of the events was unknown.  Follow-up (12MAY2021): Follow-up attempts completed. No further information expected.
Received Shingrix vaccine on Friday, 10/16/2020 at approximately 1:30PM. On the morning of Sunday,10/18/2020, at approximately 2:00AM, woke with severe dizziness. Symptoms were severe through the day and evening, and gradually disappeared on Monday, 10/19/2020. Felt better at 2:00PM (approximately 36 hours).
I see lot of chickenpox like  itchy rashes in my body . I counted around 60+ rashes .   There is no fever  . As of today , the rashed become cloudy .  There is no other symptoms . I am not particularly sure if it is because of this vaccine . I had taken mmr vaccine also on the same day along with varicella vaccine
She noticed that night after injection there was a small round circle at injection site. The next morning there was a big circle about 3 inches diameter. Her right arm itched and burned and felt really hard & was purple where the needle went in. Two nights later started breaking out in hives on chest. She took Allegra & Benadryl during 7/27 and 7/28. Pt went to a local urgent care and was told to take antihistamine on 7/28. on 8/2/22 her arm was back to normal but still had some hives on her chest and her arm itched some. Her Primary care doctor recommended over the counter antihistamine and famotidine 20mg take it twice a day until hives disappear. Her PCP recommended pre-medicating next time with Benadryl 25mg and famotidine 20mg by mouth 1-2 hrs before next dose.
I received my first Pfizer Covid shot on Feb 2, 2021 with no adverse reaction. I received my second shot on Feb 23, 2021 and had a headache/ minor migraine two days later. By the next day I was alright. On approximately May 4, 2021 (I can't recall the exact date) I briefly experienced light pain in my chest while using an under-desk elliptical at work. I am in good shape and that has never happened before. I last had an ECG in October 2020 during a physical for my job, and there were no issues at the time. The pain lasted four about a half hour and then subsided. Exactly one week later on the afternoon of May 11, I experienced the pain again at work while sitting at my desk, but that time for approximately ten minutes. I have not experienced any further pain and never saw a  doctor concerning the pain.
Patient developed hives on chest, neck, arms and hands.  Patient treated with cortisone cream.
Urinary tract infection; Dehydration; This spontaneous case from the was retrieved on 09-Mar-2022 from Vaccine Adverse Event Reporting System (VAERS) (reference number: 2129154-1) reported by other healthcare professional and concerned an 87-year-old, female patient.  The patient's medical history and concomitant medications were not reported.  On 08-Oct-2021, the patient was vaccinated with Fluad Quadrivalent (influenza vaccine, inactivated influenza virus surface antigen (subunit), egg-derived, mf59; dose: reported as '1', route of administration: intramuscular, anatomical location: left arm and indication: not reported). The batch number reported was 312845.  On the same day, the patient was vaccinated with a non-company co-suspect Pfizer BioNTech COVID-19 vaccine (tozinameran; dose: reported as '3', indication, route of administration and anatomical location: not reported). The batch number was not reported.  On 28-Oct-2021, 20 days after receiving Fluad Quadrivalent and  Pfizer BioNTech COVID-19 vaccine, the patient was admitted to emergency room for dehydration. The patient was found to have a urinary tract infection and received first dose of nitrofurantoin in the emergency department. The patent with remaining prescription was sent to the pharmacy.  On an unspecified date in 2021, the patient experienced acute kidney injury (AKI).  On 09-Nov-2021, the patient was admitted to hospital for 23 days.   On unspecified date in 2021, the patient recovered from AKI. AKI was resolved with hydration. The patient was stable off intravenous (IV) fluids although per oral (PO) intake was poor.  On 02-Dec-2021, the patient was discharged from the hospital.  The outcome of other events was not reported.  The reporter did not provide a causality assessment.  The events were assessed as serious due to hospitalization. Additionally, the events 'acute kidney injury' and urinary tract infection were considered to be medically significant by a Physician within Seqirus' Pharmacovigilance and Risk Management Department.  Company comment: An 87-year-old female patient experienced dehydration, urinary tract infection and acute kidney injury (AKI) approximately 3 weeks after vaccination with Fluad Quadrivalent and Pfizer BioNTech COVID-19 vaccines. Causality for the reported events is assessed as not related due to biological implausibility.; Sender's Comments: An 87-year-old female patient experienced dehydration, urinary tract infection and acute kidney injury (AKI) approximately 3 weeks after vaccination with Fluad Quadrivalent and Pfizer BioNTech COVID-19 vaccines. Causality for the reported events is assessed as not related due to biological implausibility.
received Infanrix instead of Boostrix; received Infanrix; This case was reported by a other health professional via call center representative and described the occurrence of wrong vaccine administered in a 12-year-old female patient who received DTPa (Infanrix) (batch number 5RM39, expiry date 25th November 2022) for prophylaxis.   Co-suspect products included dtpa vaccine pre-filled syringe device (Infanrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 24th August 2021, the patient received Infanrix and Infanrix Pre-Filled Syringe Device. On 24th August 2021, unknown after receiving Infanrix and Infanrix Pre-Filled Syringe Device, the patient experienced wrong vaccine administered and inappropriate age at vaccine administration. On an unknown date, the outcome of the wrong vaccine administered and inappropriate age at vaccine administration were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The patient received Infanrix instead of Boostrix, which led to wrong vaccine administered and inappropriate age at vaccine administration. The reporter consented to follow up.
Pt recvd 3 Engerix-B vax 0n 0,1,6 mo schedule;3 mo p/ last dose titer indicated little response.
pt recv vax; moderate fever; tongue swelled, arm turned dark red x 2 days; d for several hr the same day;
tested positive for COVID-19; was given the first COVID-19 dose. After some time, the employee got symptomatic and was tested positive for COVID-19; This is a spontaneous report from a contactable pharmacist. A patient of unspecified age and gender received the first dose of bnt162b2, via an unspecified route of administration on an unspecified date at a single dose for Covid-19 immunization. The patient's medical history and concomitant medications were not reported.  The patient who is employed in a hospital tested negative for COVID-19 then was given the first COVID-19 dose. After some time, the patient got symptomatic and was tested positive for COVID-19. The outcome of the events was unknown.   Information on the lot/batch number has been requested.; Sender's Comments: The reported information is limited. The case will be reassessed upon receipt of follow up information. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
Vaccine leaked at hub of syringe while giving vaccine.  Syringe used was a 1ml vanishpoint.  Client did receive over 1/2 the vaccine with a few drops coming out from hub of syringe. Mother present and was notified of the leakage.  Mother declines giving child a second immediate dose.  She wishes to speak with pediatrician.